CVC and GBL Initiate €10.7 Billion Takeover Bid for Italy's Recordati

• The bidders are offering €51.29 per share for Recordati
• The offer has support from Recordati's controlling shareholders
• The acquisition is backed by committed, flexible and stable financing

CVC and GBL Launch €10.7 Billion Takeover Bid for Recordati

Private equity firm CVC Capital Partners and Belgian investment group GBL announced a €10.7 billion ($12.43 billion) voluntary cash offer to acquire Italian pharmaceutical company Recordati on May 22. The bid aims to delist the company from the Milan Stock Exchange.

Key Deal Terms:

• Offer price: €51.29 per share
• Structure: Full cash acquisition through a newly formed Italian joint stock company
• Objective: Take Recordati private via delisting

Strategic Support:

The acquirers emphasized the offer is backed by a "committed, flexible and stable" structure, though specific financing details were not disclosed in the article excerpt. Notably, Recordati's controlling shareholders support the transaction, providing significant momentum for deal completion.

Companies Involved:

• Recordati (RECI.MI): Italian pharmaceutical group and target company
• CVC Capital Partners: Global private equity firm leading the acquisition
• GBL: Belgian investment group partnering with CVC

Market Implications:

This transaction represents a significant private equity play in the European pharmaceutical sector, demonstrating continued investor appetite for healthcare assets despite broader market conditions. The delisting strategy suggests the acquirers see long-term value in operating Recordati outside public market scrutiny, potentially enabling strategic restructuring or expansion initiatives.

The substantial premium typically associated with delisting offers may provide attractive exit opportunities for minority shareholders. The deal underscores ongoing consolidation trends in the pharmaceutical industry, where private equity firms increasingly target specialty pharmaceutical companies with stable cash flows and niche market positions.

The transaction awaits standard regulatory approvals and shareholder acceptance.